Considerable efforts have been made by NGS sequencing and other “omic” studies to improve the molecular characterisation of the major subtypes—luminal A (LumA), luminal B (LumB1 and B2), HER2 enriched (HER2+) and basal-like (the large majority of triple-negative breast cancer—TNBC)—and to find novel targets for personalised therapy. Here, ERBB2 is linked to triple-negative breast carcinoma.